Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 4/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.65 |
| ▸ | FES | P07332 | 2/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.56 |
| ▸ | ULK1 | O75385 | 2/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | STK25 | O00506 | 1/20 | 0.53 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | CASK | O14936 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.53 |
| ▸ | MUSK | O15146 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17731760 | 0.92 | TTK (0.72) | TTKALKFESFLT3ZAP70 | |
| SCHEMBL17731734 | 0.92 | TTK (0.73) | TTKALKFESFLT3ZAP70 | |
| SCHEMBL17731693 | 0.86 | TTK (0.61) | TTKALKFESFLT3DCLK1 | |
| SCHEMBL14866452 | 0.84 | ALK (0.89) | TTKALKFESFLT3ZAP70 | |
| SCHEMBL17731758 | 0.83 | TTK (0.75) | TTKALKFESFLT3ZAP70 | |
| SCHEMBL17731737 | 0.82 | TTK (0.64) | TTKALKZAP70PTK2INSR | |
| SCHEMBL17731736 | 0.82 | TTK (1.00) | TTKALKFESFLT3ZAP70 | |
| SCHEMBL14866431 | 0.81 | TTK (0.73) | TTKALKFESFLT3ZAP70 | |
| SCHEMBL14866428 | 0.80 | TTK (0.72) | TTKALKFESFLT3ZAP70 | |
| SCHEMBL3959447 | 0.80 | TTK (0.72) | TTKALKFESFLT3ZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2020-04-07 | — | — | US | disclosed |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2020-04-07 | — | — | US | disclosed |
| US-20190106422-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2019-04-11 | — | — | US | disclosed |
| US-20190106422-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2019-04-11 | — | — | US | disclosed |
| WO-2016073771-A2 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106422-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | TTBK1, TTK, TTBK2 | TTK 2/4885ALK 1264/4885FES 95/4885 |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | TTBK1, TTK, TTBK2 | TTK 2/4885ALK 1264/4885FES 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.